Pancreatic ductal adenocarcinoma (PDAC) represents a leading cause of cancer death and is often diagnosticated too late to allow adequate treatments. Lots of biomarkers have been discovered in lasts years but, to date, there is a lack of low-cost and non-invasive tools for PDAC early detection. Nonetheless, drugs commonly used in PDAC treatment do not allow achieving long-term satisfying results. Nanotechnology is gaining importance in both PDAC early detection and treatment. The main implications of nanotechnology in cancer diagnosis lay in the ability that nanoparticles have on concentrate the alteration in human proteome caused by cancer. Nanoparticle-enabled blood tests have been demonstrated to reach high rate of sensitivity (up to 85%) and specificity (up to 100%). In the field of cancer therapy nanoparticles can be used as nanocarriers able to reach specific tumour's cells and selectively release the drug they contain into them. A literature review was carried out with the aim to assess the state of the art and highlight the future perspectives of nanotechnology in PDAC early detection and therapy.

Nanotechnology and pancreatic cancer management: State of the art and further perspectives / Caputo, D.; Pozzi, D.; Farolfi, T.; Passa, R.; Coppola, R.; Caracciolo, G.. - In: WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. - ISSN 1948-5204. - 13:4(2021), pp. 197-311. [10.4251/WJGO.V13.I4.231]

Nanotechnology and pancreatic cancer management: State of the art and further perspectives

Pozzi D.;Caracciolo G.
2021

Abstract

Pancreatic ductal adenocarcinoma (PDAC) represents a leading cause of cancer death and is often diagnosticated too late to allow adequate treatments. Lots of biomarkers have been discovered in lasts years but, to date, there is a lack of low-cost and non-invasive tools for PDAC early detection. Nonetheless, drugs commonly used in PDAC treatment do not allow achieving long-term satisfying results. Nanotechnology is gaining importance in both PDAC early detection and treatment. The main implications of nanotechnology in cancer diagnosis lay in the ability that nanoparticles have on concentrate the alteration in human proteome caused by cancer. Nanoparticle-enabled blood tests have been demonstrated to reach high rate of sensitivity (up to 85%) and specificity (up to 100%). In the field of cancer therapy nanoparticles can be used as nanocarriers able to reach specific tumour's cells and selectively release the drug they contain into them. A literature review was carried out with the aim to assess the state of the art and highlight the future perspectives of nanotechnology in PDAC early detection and therapy.
2021
Biomarkers; Early detection; Nanoparticles; Nanotechnology; Pancreatic ductal adenocarcinoma; Protein corona
01 Pubblicazione su rivista::01a Articolo in rivista
Nanotechnology and pancreatic cancer management: State of the art and further perspectives / Caputo, D.; Pozzi, D.; Farolfi, T.; Passa, R.; Coppola, R.; Caracciolo, G.. - In: WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY. - ISSN 1948-5204. - 13:4(2021), pp. 197-311. [10.4251/WJGO.V13.I4.231]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1706131
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 24
social impact